Global biotech BioMarin Pharmaceutical Inc. (BMRN) has announced updated results of an open-label Phase 1/2 study of valoctocogene roxaparvovec, an investigational gene therapy …
BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) announced an offering, subject to market and other conditions, of 7,500,000 shares of its common stock in an underwritten …
Oppenheimer analyst Christopher Marai came out today with a few insights on BioMarin Pharmaceutical Inc. (NASDAQ:BMRN), after attending the FDA advisory meeting for Kyndrisa, the company’s treatment for Duchenne …
Following the annual J.P.
